The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
N0321: A phase II study of bortezomib, paclitaxel, carboplatin (CBCDA), and radiotherapy (RT) for locally advanced non-small cell lung cancer (NSCLC).
Steven E. Schild
No relevant relationships to disclose
Nathan R. Foster
No relevant relationships to disclose
Julian R. Molina
No relevant relationships to disclose
Grace K. Dy
No relevant relationships to disclose
Kendrith M. Rowland
No relevant relationships to disclose
Jann Nagina Sarkaria
No relevant relationships to disclose
Sachdev P. Thomas
No relevant relationships to disclose
Donald W. Northfelt
No relevant relationships to disclose
John William Kugler
No relevant relationships to disclose
Alex A. Adjei
No relevant relationships to disclose